The Pharmacological Studies on Dimetacrine I. Studies on the Absorption, Distribution and Excretion of H3-Labeled Dimetacrine in the Rat

Total Page:16

File Type:pdf, Size:1020Kb

The Pharmacological Studies on Dimetacrine I. Studies on the Absorption, Distribution and Excretion of H3-Labeled Dimetacrine in the Rat THE PHARMACOLOGICAL STUDIES ON DIMETACRINE I. STUDIES ON THE ABSORPTION, DISTRIBUTION AND EXCRETION OF H3-LABELED DIMETACRINE IN THE RAT RYOICHI ISHITANI*, KENTARO SAITO* AND HARUO KITAGAWA** *Departmentof Researchand Development, HitachiChemical Company Limited, Honkomagome, Bunkyo-ku, Tokyo **Departmentof BiochemicalPharmacology , Facultyof PharmaceuticalSciences, University of Chiba,Chiba Receivedfor publication March 4, 1970 Dimetacrine, 10-[3(dimethylamino)propyl]-9,9-dimethylacridan, is a tricyclic com pound with a central hexagonal ring instead of the heptagonal ring common to most anti depressants. The synthesis and chemistry of this compound have been reported by Molnar et al. (1). The unique pharmacological properties of dimetacrine as a reserpine antagonism, central parasympathicolytic action and the occurrence of behavioral changes in cats and rats were observed by Jahn (2). The clinical properties and the value of this drug in the treatment of depressive states, and in a variety of psychic disorders have been well established (3-5). Schatz et al. (6) demonstrated the metabolic fate of dimetacrine by means of colori metric assay based on the method of Herrmann et al. (7). However, the sensitivity of this method is relatively low for detection of dimetacrine and its metabolites, therefore, the present paper was undertaken to determine the metabolic patterns of this drug using radio metric assay. MATERIALSAND METHODS 1. H'-Dimetacrine Labeled dimetacrine with a specific activity of 22 pCi/mg was synthesized according 石 谷 良一 ・斉 藤 堅 太 郎 ・北 川 晴 雄 to the method of Eidinoff et al. (8), using a tritium water as labeled precursor. The final product was chemically and radiochemically pure which was determined by mixed melt ing points with authentic dimetacrine and by paper chromatography in the following solvent system-toluene : ether: formic acid (10: 10: 5) and MeOH : 28-29% ammonia water (1: 1). 2. Animals Male Wistar rats (200-250 g) were given 20 mg/kg , (0.44 mCi/kg) of H3-dimetacrine orally or intraperitoneally. All animals used here were fasted overnight before experiments. 3. Assay proceduresof H'-dimetacrinefrom biological materials 1) Drug concentrationsin blood Blood specimens were withdrawn from tail vein at points indicated in Fig. 1. An aliquot of blood (0.02 ml) was adsorbed on filter paper and kept overnight at room tem perature to dryness and then combusted using the combustion apparatus described' else where in this paper. 2) Distribution of the drug in tissues The animals were decapitated at appropriate time intervals after drug administration, the chest was opened and bled as much as possible from the heart. Tissues were removed, blotted, weighed and homogenized in 4 volumes of water with a motor driven Potter Elvehjem homogenizer. An aliquot of tissue homogenates was lyophilized. The materials were weighed, carefully ground, and an aliquot of this materials no more than 50 mg was combusted using a combustion apparatus. The combustion method have been reported by several investigators (9-12) and in this paper, the dry combustion method as described by Baba et al. (13) was used. The resulting tritium water after combustion was collected by condensation in dry ice-acetone mixture and the condensed tritium water was eluted three times into counting vials with dioxane phosphor (14) in the volumes of 10, 5 and 3 ml. Over 98% of the radioactivity, when H'-dimetacrine was added to control tissues prior to homogenization under the condition described above, was recovered from the homogenates. 3) Excretion of drug in urine,feces and bile Urine and feces were collected separately in metabolism cages, in which rats were given H'-dimetacrine in a dose of 20 mg/kg (0.44 mCi/kg) orally or intraperitoneally. For determination of H'-radioactivity in bile, a 24 hour bile was collected from the rats given 20 mg/kg (0.44 mCi/kg) of H'-dimetacrine orally. Radioactivities of feces were measured as the dry combustion method described elsewhere in this paper. Urine and bile were diluted to 50-100 ml with water and radioactivities in aliquots (0.5 ml or 1.0 ml) of diluted samples were measured in counting vials containing 15 ml of dioxane phosphor. Counting H3-radioactivity was counted in the Beckman liquid scintillation spectrometer DPM 100, using a dioxane phosphor. The counts (cpm) were converted to disintegrations per minute (dpm) by the use of the channel ratio method. Using the combustion method, H3-radioactivity was assayed at 45% efficiency and in biliary excretion studies, counting efficiency was 33%. RESULTS 1. Absorption of H3-dimetacrineand its average half-life in blood Blood specimens of rats given H'-dimetacrine, either orally or intraperitoneally, were withdrawn from tail vein at appropriate times and were assayed for total radioactivity. Appreciable amounts of radioactivity were found in the whole blood 0.5 hour after administration by either routes and the highest concentration was observed at 1 hour after intraperitoneal administration and thereafter declined, with an average half-life of approxi mately 10 hours. On the other hand, the maximum concentration of the drug was found within 1 hour after oral administration and this level was thereafter maintained for additional 6-8 hours and then declined, with an average half-life of approximately 24 hours. In both routes, the levels of the drug declined to about 17-14% of the maximum con centration within 72 hours after drug administration. FIG. 1. Concentration of total radioactivity in whole blood. Rats were given 20 mg/kg (0.44 mCi/kg) of H3-dimetacrine in the two routes used. 2. Distribution of H3-dimetacrinein tissues After oral administration of H3-dimetacrine, the animals were decapitated at various times indicated and the total radioactivities of tissues were assayed (Tables 1 and 2). There were appreciable concentrations of radioactivity in all tissues at 0.5 hour after administration. The highest concentrations of radioactivity was found at 1 hour after administration but at 3 hours in brain, heart, lung, liver, spleen, kidney, skeletal muscle and adipose tissue of testes. At all time intervals investigated, the concentration of radioactivity (percentage of dose per gram tissue) in the lung was the highest among all tissues investigated. As shown in Table 2, the concentration of total radioactivity in stomach and small intestine was the highest at 1 hour, and 72 hours later, the total radioactivity in these tis sues declined to as little as 1.03% of the dose administered. Recovery of H'-radioactivity from tissues, urine and feces at 1 hour, 3 hours, 12 hours, 24 hours and 48 hours was 63.83%, 56.99%, 53.80%, 52.19% and 71.44%, respectively. In Table 2, the values of blood, skeletal muscle and adipose tissue are not recorded. TALE 1. Total radioactivity in rat tissues at various times after oral administration of H3 dimetacrine. Fifteen rats were given 20 mg/kg (0.44 mCi/kg) of H3-dimetacrine orally. At inter vals three rats were killed for assay. Results are expressed as percentage of dose per gram of tissue. Average values are given with the range shown in brackets. 3. Excretion of radioactivityafter H'-dimetacrine administration Rats were given H'-dimetacrine orally and intraperitoneally. Urine and feces were collected at 12, 24 and 48 hours after administration and assayed for their total radio TABLE2. Total radioactivity in rat tissues, small intestine and excreta at various times after oral administration of H3-dimetacrine. Fifteen rats were given 20 mg/kg (0.44 mCi/kg) of H3-dimetacrine orally. At intervals three rats were killed for assay. Results are expressed as percentage of dose per total weight of specimens. Average values are given with the range shown in brackets. TABLE3. Urinary and fecal excretion of radioactivity after intraperitoneal administration of H3-dimetacrine. Three rats were given 20 mg/kg (0.44 mCi/kg) of H3-dimetacrine intraperitoneally. Results are expressed as percentage of dose. Average values are given with the range shown in brackets. activity (Tables 2 and 3). When administered by the two routes, approximately 70% of the doses was excreted in urine and feces within 2 days after treatment. As shown in Tables 2 and 3, feces at 1, 3 and 12 hours and urine at 1 and 3 hours later were difficult to collect, therefore, radioactivities of these samples were not determined. Within 24 hours after oral administration, 24.15% of the dose was eliminated in bile. The decrease of the radioactivity in the liver TABLE4. Biliary excretion of radioactivity during this period probably reflects excre after oral administration of H3-dimeta crine. tion into the bile. Rats were given 20 mg/kg (0.44 mCi/ kg) of H3-dimetacrine orally. Bile was DISCUSSION collected for 24 hours and assayed for total radioactivity. Results are ex The highest concentration of radioac pressed as percentage of dose. tivity in whole blood after oral administra tion of H'-dimetacrine was observed at 1 hour and continued for 6-8 hours there after. The prolonged action of the pharma cological effects of dimetacrine perhaps is the reflection of its long half-life in the blood. At 3 hours after oral administration, the total radioactivity in the liver was 11 9% of the administered dose, and declined to 1.09% within 48 hours; on the other hand, 24.15% of dose was excreted in bile within 24 hours. These results suggest that the portal circula tion is involved in absorption and excretion of this drug. In studying the distribution of this drug, the sum of radioactivities of brain, heart, lung, liver, kidney and spleen was 1.54% of the administered dose at 48 hours after oral ad ministration; accumulation of the drug was not observed. The total radioactivities in excreta were found at the levels of 68.87 and 75.04% of dose at 48 hours after administra tion by the two routes, i.e., i.p.
Recommended publications
  • 2019 Instrumentation and Consumable Catalog 2 INSTRUMENTATION and CONSUMABLE CATALOG
    PRODUCT CATALOG 2019 Instrumentation and Consumable Catalog 2 INSTRUMENTATION AND CONSUMABLE CATALOG Resolvex® A200 Part Numbers: A200 96: 253-1160 Resolvex® A200 96 Resolvex A200 Standalone work station for automated sample preparation. The compact benchtop offers the one stop solution for automating sample preparation utilizing creation of multiple work flows, and programmable dispensing of up to 11 solvents. Along with its innovative positive pressure system leading to clean samples, improving accuracy, throughput and enhancing the Life time of your analytical instrument. The A200 comes with an easy to use touch screen interface allowing for easy set up of multiple work flows. In addition the light curtain safety feature will release gas pressure when manifold is activated to prevent any injuries. INSTRUMENTATION AND CONSUMABLE CATALOG 3 Resolvex® A100 Part Numbers: A100 96: 253-0019 A100 48: 253-0014 Resolvex® A100 Standalone work station for automated sample preparation. The compact benchtop offers the one stop solution for automating sample preparation utilizing creation of multiple work flows, and programmable dispensing of up to 11 solvents. Along with its innovative positive pressure system leading to clean samples, improving accuracy, throughput and enhancing the Life time of your analytical instrument. The A100 comes in 96 and 4 configuration allowing for for automated Work Flow solutions in multiple SPE formats. 4 INSTRUMENTATION AND CONSUMABLE CATALOG Resolvex® M10 96/M10 96 XT/M10 48 Part Numbers: M10 96 XT: 288-0006 M10 96: 288-0001 M10 48: 289-0004 Resolvex® M10 Standalone work station for Positive Pressure solid phase extraction. The manual Resolvex M10 48 and 96 are positive pressure manifold for 1, 3, and 6 ml cartridges, or 1ml 96 well plates.
    [Show full text]
  • Gps' Drug Treatment for Depression by Patients' Educational Level
    RESEARCH GPs’ drug treatment for depression by patients’ educational level: registry- based study Anneli Borge Hansen, MD1,2*, Valborg Baste, MSc. Statistics, PhD1, Oystein Hetlevik, MD, PhD1,2, Inger Haukenes, MSc. Philosophy, PhD1,2, Tone Smith- Sivertsen, MD, PhD1,3, Sabine Ruths, MD, PhD1,2 1Research Unit for General Practice, NORCE Norwegian Research Centre, Bergen, Norway; 2Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway; 3Division of Psychiatry, Haukeland University Hospital, Bergen, Norway Abstract Background: Antidepressant drugs are often prescribed in general practice. Evidence is conflicting on how patient education influences antidepressant treatment. Aim: To investigate the association between educational attainment and drug treatment in adult patients with a new depression diagnosis, and to what extent sex and age influence the association. Design & setting: A nationwide registry- based cohort study was undertaken in Norway from 2014– 2016. Method: The study comprised all residents of Norway born before 1996 and alive in 2015. Information was obtained on all new depression diagnoses in general practice in 2015 (primary care database) and data on all dispensed depression medication (Norwegian Prescription Database [NorPD]) 12 months after the date of diagnosis. Independent variables were education, sex, and age. Associations with drug treatment were estimated using a Cox proportional hazard model and performed separately for sex. *For correspondence: ahan@ Results: Out of 49 967 patients with new depression (61.6% women), 15 678 were dispensed drugs norceresearch. no (30.4% women, 33.0% men). Highly educated women were less likely to receive medication (hazard ratio [HR] = 0.93; 95% confidence interval [CI] = 0.88 to 0.98) than women with low education.
    [Show full text]
  • 1 Supplemental Figure 1: Illustration of Time-Varying
    Supplemental Material Table of Contents Supplemental Table 1: List of classes and medications. Supplemental Table 2: Association between benzodiazepines and mortality in patients initiating hemodialysis (n=69,368) between 2013‐2014 stratified by age, sex, race, and opioid co‐dispensing. Supplemental Figure 1: Illustration of time‐varying exposure to benzodiazepine or opioid claims for one person. Several sensitivity analyses were performed wherein person‐day exposure was extended to +7 days, +14 days, and +28 days beyond the outlined periods above. 1 Supplemental Table 1: List of classes and medications. Class Medications Short‐acting benzodiazepines Alprazolam, estazolam, lorazepam, midazolam, oxazepam, temazepam, and triazolam Long‐acting benzodiazepines chlordiazepoxide, clobazam, clonazepam, clorazepate, diazepam, flurazepam Opioids alfentanil, buprenorphine, butorphanol, codeine, dihydrocodeine, fentanyl, hydrocodone, hydromorphine, meperidine, methadone, morphine, nalbuphine, nucynta, oxycodone, oxymorphone, pentazocine, propoxyphene, remifentanil, sufentanil, tapentadol, talwin, tramadol, carfentanil, pethidine, and etorphine Antidepressants citalopram, escitalopram, fluoxetine, fluvozamine, paroxetine, sertraline; desvenlafaxine, duloxetine, levomilnacipran, milnacipran, venlafaxine; vilazodone, vortioxetine; nefazodone, trazodone; atomoxetine, reboxetine, teniloxazine, viloxazine; bupropion; amitriptyline, amitriptylinoxide, clomipramine, desipramine, dibenzepin, dimetacrine, dosulepin, doxepin, imipramine, lofepramine, melitracen,
    [Show full text]
  • Info on Skin Testing
    Information on Skin Testing *Please review 1 week prior to testing* Your Doctor has ordered an allergy test for you. Your appointment has been made for: ___________________________________ at _______________________AM/PM at our (date) (time) _ Foulkstone / Limestone / Glasgow _ office. Skin tests are a method of testing for allergic reactions to substances, or allergens, in the environment. Our practice utilizes a test that involves no needles! We use a prick method which involves a series of small plastic applicators that carry a specific antigen which is placed on your arms. The types of allergens we test for include weeds, trees, grasses, molds, animal dander, dust mites and some foods. The testing will take 45 minutes. Please remember to wear comfortable clothing with short sleeves. Reactions can consist of itchy eyes, nose or throat, nasal congestion, runny nose, tightness in the throat or chest, wheezing, lightheadedness, hives or anaphylactic shock. Although this is very rare, our staff is fully prepared with emergency equipment and a physician is always on site. To ensure accurate testing results, certain medicines should be stopped 5 days prior to testing, although you should not stop medicines without talking to your prescribing physician. Medications that interfere with testing include but are not limited to: Antihistamines are medicines used to treat allergies, nausea, and dizziness. Many are found in over the counter cold medicines. They include, but are not limited to: ALAVERT / CLARITIN (LORATIDINE) DRAMAMINE (DIMENHYDRINATE)
    [Show full text]
  • In Utero Exposure to Antidepressant Drugs and Risk of Attention Deficit Hyperactivity Disorder (ADHD)
    FACULTY OF HEALTH SCIENCE; AARHUS UNIVERSITY In utero exposure to antidepressant drugs and risk of attention deficit hyperactivity disorder (ADHD): A nationwide Danish cohort study Research year report Kristina Laugesen Department of Clinical Epidemiology, Aarhus University Hospital Supervisors Henrik Toft Sørensen, MD, PhD, DMSc, professor (main supervisor) Department of Clinical Epidemiology Aarhus University Hospital Denmark Morten Olsen, MD, PhD (co-supervisor) Department of Clinical Epidemiology Aarhus University Hospital Denmark Ane Birgitte Telén Andersen, PhD-student, MPH (co-supervisor) Department of Clinical Epidemiology Aarhus University Hospital Denmark Preface This study was carried out during my research year at Department of Clinical Epidemiology, Aarhus University Hospital, Denmark (February 2012 - January 2013). I would like to express my gratefulness to my main supervisor Henrik Toft Sørensen and the Department of Clinical Epidemiology. This department contributes to research of high standard and I feel lucky to have been a part of the research environment here. From my point of view a research environment of high standard originates not only from bright and innovative people but also from the ability to work together, share knowledge and ideas and make use of people´s different skills, all qualities possessed by this department. Thank you for having introduced me to epidemiological research, I have definitely been encouraged to continue research in this field. Also I would like to say thank you for giving me the possibility to go to Boston for three months during my research year. It has been an experience of great personal and intellectual gain. A special thanks to Elizabeth Hatch who have warmly welcomed us at the Department of Public Health, Boston University.
    [Show full text]
  • Conflicts of Interest and Outcomes of Clinical Trials of Antidepressants An
    Journal of Psychiatric Research 116 (2019) 83–87 Contents lists available at ScienceDirect Journal of Psychiatric Research journal homepage: www.elsevier.com/locate/jpsychires Conflicts of interest and outcomes of clinical trials of antidepressants: An 18- year retrospective study T ∗ Ahmed Waqasa, ,1, Ammad Anwar Baiga,1, Muhammad Ali Khalida, Kapil Kiran Aedmab, Sadiq Naveedc a CMH Lahore Medical College & Institute of Dentistry, Lahore Cantt., Pakistan b KVC Health Systems, Kansas City, KS, USA c Kansas University Medical Centre, Kansas City, KS, USA ARTICLE INFO ABSTRACT Keywords: Pharmaceutical sponsorship, funding sources, and investigators’ conflicts of interest may be potential influencers Conflict of interest in the conduct and results of clinical trials, as well as in the promotion of psychiatric drug therapies. We report Funding the results of an audit of randomized controlled trials (RCTs) of antidepressants conducted from 2000 to 2017. Ethics We searched the Web of Science databases with a comprehensive search strategy to identify phase 2 and 3 RCTs. Trials Out of the 1085 articles initially located, a total of 291 RCTs were identified and included in the final analyses. A RCT higher percentage of RCTs conducted by employees of pharmaceutical companies reported favorable results than Antidepressants those with academic or governmental funding (76.90% vs. 60.60%); however, this association was not sig- nificant (Χ2 = 2.47, P = 0.18). The data were further analyzed using bivariate and cluster analytical approaches, and the nonsignificant association persisted in both cases. However, analyses of industry-funded placebo-con- trolled trials (a subgroup of the 291 RCTs) revealed a higher proportion of results that were reported as sig- nificant compared to their counterparts with other funding sources (67% vs.
    [Show full text]
  • Beta Blockers Herbs
    Accredited Asthma, Allergy, & Food Intolerance Center • 1009B Dupont Square North • Louisville, KY • 40207 • Phone (502)895 -3330 • Fax (502)895-3356 IMPORTANT LIST OF MEDICATIONS TO AVOID - REVIEW IMMEDIATELY ANTIHISTAMINES ANTIHISTAMINES (CONT.) TRICYCLIC ANTIDEPRESSANTS **STOP 10 days PRIOR TO TESTING** **STOP 2 DAYS or 48 Hours PRIOR TO TESTING** **STOP 10 days PRIOR TO TESTING** GENERIC NAME BRAND NAME GENERIC NAME BRAND NAME **Please contact the ordering physician Azelastine Astelin Acrivastine Semprex-D before stopping these medications.** Azelastine Optivar Olopatadine Pataday Cetirizine Zyrtec GENERIC NAME BRAND NAME Chlorcyclizine HCl Ahist Amitriptyline Elavil Chlorcyclizine HCl Stahist Medications for Dizziness/Motion Amitriptyline Endep Chlorpheniramine Aller-Chlor Sickness Amitriptyline Etrafon Chlorpheniramine Chlo-Amine **STOP 10 DAYS PRIOR TO TESTING** Amitriptyline Laroxyl Chlorpheniramine Chlorphen GENERIC NAME BRAND NAME Amitriptyline Limbitrol Chlorpheniramine Chlor-Trimeton Meclizine Hydrochloride Antivert Amitriptyline Tryptizol Chlorpheniramine C.P.M. Meclizine Dramamine Amitriptyline Vanatrip Chlorpheniramine Effidac-24 Amitriptylinoxide Ambivalon Chlorpheniramine Ridraman Amitriptylinoxide Amioxid Cimetidine Tagamet Amitriptylinoxide Equilibrin Clemastine Allerhist-1 BETA BLOCKERS Amoxampine Asendin Clemastine Contac 12 Hour Allergy **DO NOT TAKE these medications the MORNING Butriptyline Evadyne Clemastine Tavist-1 OF your appointment** Clomipramine Anafranil Cyproheptadine Periactin GENERIC NAME BRAND NAME
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,560,544 B2 Webber Et Al
    USOO756.0544B2 (12) United States Patent (10) Patent No.: US 7,560,544 B2 Webber et al. (45) Date of Patent: Jul. 14, 2009 (54) 3.5-DISUBSITITUTED AND 2003.01.00764 A1 5/2003 Bonket al. 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 2003,01628.06 A1 8, 2003 Dellaria et al. 3H-THIAZOLO4,5-DIPYRIMIDIN-2-ONE 2003/0176458 A1 9, 2003 Dellaria et al. COMPOUNDS AND PRODRUGS THEREOF 2003/0186949 A1 10, 2003 Dellaria et al. 2003. O195209 A1 10, 2003 Dellaria et al. (75) Inventors: Stephen E. Webber, San Diego, CA S-8. A. 1929 St.oberts etet al. al. (US); Gregory J. Haley, Del Mar, CA 2005, 0004144 A1 1/2005 Carson et al. (US); Joseph R. Lennox, San Diego, CA (US); Alan X. Xiang, San Diego, CA FOREIGN PATENT DOCUMENTS (US); Erik J. Rueden, Santee, CA (US) EP O 882 727 9, 1998 EP 1 035 123 9, 2000 (73) Assignee: Anadys Pharmaceuticals, Inc., San EP 1043 021 10, 2000 Diego, CA (US) EP 1386,923 A1 2, 2004 WO WO-89/05649 6, 1989 Notice: Subject to any disclaimer, the term of this WO WO-92, 16215 10, 1992 (*) WO WO-94,07904 4f1994 patent is extended or adjusted under 35 WO WO-94, 17043 8, 1994 U.S.C. 154(b) by 119 days. WO WO-94.17090 8, 1994 WO WO-98, 17279 4f1998 (21) Appl. No.: 11/304,691 WO WO-03/045968 6, 2003 (22) Filed: Dec. 16, 2005 OTHER PUBLICATIONS Vippagunta et al. Advanced Drug Delivery Reviews 48 (2001)3-26.* (65) Prior Publication Data Lugemwaetal.
    [Show full text]
  • Esketamine for the Treatment of Treatment-Resistant Depression: Effectiveness and Value
    Esketamine for the Treatment of Treatment-Resistant Depression: Effectiveness and Value Evidence Report May 9, 2019 Prepared for ©Institute for Clinical and Economic Review, 2019 The University of Illinois at Chicago College of ICER Staff and Consultants Pharmacy’s Center for Pharmacoepidemiology and Pharmacoeconomic Research* Steven J. Atlas, MD, MPH Daniel R. Touchette, PharmD, MA Associate Professor of Medicine Professor of Pharmacy Harvard Medical School, Boston Assistant Director, Center for Pharmacoepidemiology Director, Practice Based Research & Quality and Pharmacoeconomic Research Improvement University of Illinois at Chicago Division of General Internal Medicine Massachusetts General Hospital, Boston Nicole Boyer, PhD Research Fellow Foluso Agboola, MBBS, MPH University of Chicago Director, Evidence Synthesis Institute for Clinical and Economic Review Brian Talon, PharmD PhD Student University of Illinois at Chicago Katherine Fazioli Senior Research Assistant Bob G. Schultz, PharmD Institute for Clinical and Economic Review PhD Student and Research Fellow University of Illinois at Chicago Varun M. Kumar, MBBS, MPH, MSc Associate Director of Health Economics Institute for Clinical and Economic Review *The role of the University of Illinois at Chicago College of Ellie Adair, MPA Pharmacy’s Center for Pharmacoepidemiology and Program Manager Pharmacoeconomic Research is limited to the development of the cost-effectiveness model, and the resulting ICER reports do not Institute for Clinical and Economic Review necessarily represent the views of the UIC. David Rind, MD Chief Medical Officer Institute for Clinical and Economic Review Steve Pearson, MD, MSc President Institute for Clinical and Economic Review Date of Publication: May 9, 2019 Steven Atlas served as the lead author for the report.
    [Show full text]
  • Resistant Depression: Effectiveness and Value
    Esketamine for the Treatment of Treatment- Resistant Depression: Effectiveness and Value Draft Evidence Report March 21, 2019 Prepared for ©Institute for Clinical and Economic Review, 2019 The University of Illinois at Chicago College of ICER Staff and Consultants Pharmacy’s Center for Pharmacoepidemiology and Pharmacoeconomic Research* Steven J. Atlas, MD, MPH Daniel R. Touchette, PharmD, MA Associate Professor of Medicine Professor of Pharmacy Harvard Medical School, Boston Assistant Director, Center for Pharmacoepidemiology Director, Practice Based Research & Quality and Pharmacoeconomic Research Improvement University of Illinois at Chicago Division of General Internal Medicine Massachusetts General Hospital, Boston Nicole Boyer, PhD Research Fellow Foluso Agboola, MBBS, MPH University of Chicago Director, Evidence Synthesis Institute for Clinical and Economic Review Brian Talon, PharmD PhD Student University of Illinois at Chicago Katherine Fazioli Senior Research Assistant Bob G. Schultz, PharmD Institute for Clinical and Economic Review PhD Student and Research Fellow University of Illinois at Chicago Varun Kumar, MBBS, MPH, MSc Associate Director of Health Economics Institute for Clinical and Economic Review Ellie Adair, MPA Program Manager Institute for Clinical and Economic Review David Rind, MD Chief Medical Officer Institute for Clinical and Economic Review *The role of the University of Illinois at Chicago College of Pharmacy’s Center for Pharmacoepidemiology and Pharmacoeconomic Research is limited to the development of the Steve Pearson, MD, MSc cost-effectiveness model, and the resulting ICER reports do not President necessarily represent the views of the UIC. Institute for Clinical and Economic Review Date of Publication: March 21, 2019 Steve Atlas served as the lead author for the report.
    [Show full text]
  • Carrollton 2017 BEST
    Dr. Justin Northeim Medical Director ________________________________ Medical Director ________________________________ Chief ________________________________ Protocol Effective Date ________________________________ Department License Expiration Date Table of Contents Section One: General Information!..........................................................7 • Aero-medical Transport Guidelines: 7 • Cessation of Efforts: 7 • Consent/Refusal of Treatment: 8 • Controlled Substances: 11 • Do Not Resuscitate (DNR): 12 • EMS Patient Care Report: 14 • Immobilization Standards: 14 • Infectious Disease: 16 • Inter-Hospital Emergency Transfers: 16 • Mass Casualty Incident: 17 • Medical Control: 21 • Ongoing Skills and Competencies: 21 • Out of City Response: 21 • Restraint Policy: 21 • Resuscitation Guidelines: 23 • Run Review Process: 23 • Scope of Practice: 24 • Standing Orders: 25 • Transportation Guidelines: 25 • Unknown Health Care Professional at Scene: 27 Section Two: Patient Assessment!........................................................29 • Capnography: 29 • Initial Patient Assessment: 30 • History and Physical—Medical Patient: 31 • History and Physical—Trauma Patient: 31 • Intravenous Access/Fluids: 31 • Neurological Assessment: 32 • Patient Movement: 33 • Scene Size-Up: 33 • Triage: 34 • Twelve Lead EKG: 34 *These protocols are not to be copied or distributed without written consent from BEST EMS 1 • Vital Signs: 35 Section Three: Medical Protocols!.........................................................37 • Allergic Reactions
    [Show full text]
  • Supplemental Digital Content 1 Search Strategy (First Conducted on January 17, 2014; Second Retrieval on November 5, 2014)
    Supplemental Digital Content 1 Search strategy (first conducted on January 17, 2014; second retrieval on November 5, 2014) Cochrane Central Register of Controlled Trials and MEDLINE via OVID 1. exp chronic pain/ 2. Pain Management/ 3. Pain Measurement/ 4. pain*.mp. 5. 1 or 2 or 3 or 4 11. exp neoplasms/ 12. (neoplas* or cancer* or tumor* or tumour* or carcinoma* or malignan* or oncolog* or metasta* or sarcoma* or adenocarcinoma* or choriocarcinoma* or leukemia* or leukaemia*).mp. 13. 11 or 12 14. exp Anticonvulsants/ or exp Antidepressive Agents/ 15. (anticonvulsant* or antiepilept* or antidepressant* or anti-convulsant* or anti-epilept* or anti-depressant*).mp. 16. (acetazolamide or carbamazepine or clonazepam or divalproex or ethosuximide or ethotoin or felbamate or fosphenytoin or gabapentin or lacosamide or lamotrigine or levetiracetam or methsuximide or oxcarbazepine or phenobarbital or phenobarbitone or phenytoin or pregabalin or primidone or tiagabine or topiramate or trimethadione or valproate or valproic or vigabatrin or zonisamide).mp. 17. (agomelatine or amesergide or amineptine or amitriptyline or amoxapine or aripiprazole or benactyzine or brofaromine or bupropion or butriptyline or chlorimipramine or cianopramine or citalopram or clomipramine or clorgyline or clovoxamine or demexiptiline or desipramine or desvenlafaxine or dibenzepin or dimetacrine tartrate or dosulepin or dothiepin or doxepin or duloxetine or escitalopram or etoperidone or femoxetine or fezolamine fumarate or fluoxetine or fluvoxamine or ifoxetine or imipramine
    [Show full text]